Whilst CAR-T cell therapies have found considerable success in targeting hematological malignancies, major hurdles remain in the solid tumor space. Novel targets such as claudin 18.2 (CLDN18.2), and innovative strategies have led to encouraging results in solid tumors. In this podcast, we will hear from Gregory P. Botta, MD, PhD, UC San Diego Medical Center, San Diego, CA, Jon Amund Kyte, MD, PhD, University of Oslo, Oslo, Norway, Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, and Andras Heczey, MD, Baylor College of Medicine, Houston, TX, as they share their expert insights in this ever-expanding field.